Navigation Links
Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis
Date:1/23/2009

VIENNA, Austria, Jan. 23 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) today announced that the Australian Therapeutic Goods Administration (TGA) granted product approval for the company's vaccine to prevent Japanese Encephalitis. This final decision step for the new vaccine follows the positive recommendation provided by Australian Drug Evaluation Committee (ADEC) in December 2008.

This decision of the Australian authorities represents the first regulatory approval for the vaccine in any country. Intercell has been successfully advancing parallel regulatory processes in all key markets for travelers and military personnel with an imminent product approval in the U.S. Following the CHMP positive opinion of the European Medicines Agency (EMEA) obtained in December 2008, the approval by the European Union providing formal market authorization for all 27 member states as well as for Norway and Iceland will follow within the next weeks according to the defined EMEA process.

"We are very pleased that all approval processes for our novel Japanese Encephalitis vaccine have proceeded in line with our planned timelines. We are now moving forward to bring this important product to both travelers and military personnel in early 2009," states Thomas Lingelbach, Chief Operating Officer of Intercell.

Japanese Encephalitis is a deadly disease that kills as many as 30% of those who manifest the disease. Japanese Encephalitis is only becoming a larger risk for travelers. There is increasing travel to rural areas where the disease is more common, and climate change is extending the range of disease-carrying mosquitoes.

Intercell's vaccine will be the only registered JE-vaccine available in the Australian market and will be distributed and marketed by CSL Biotherapies Pty Ltd., which has the exclusive right for marketing and distribution of the novel cell culture-based vaccine in Australia,
'/>"/>

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SenesTech, Inc. Commences Product Registration Process With Australian Government
2. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
6. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
7. ScienceFirst Staff Expansion
8. Varian, Inc. Announces First Quarter 2009 Preliminary Results
9. Verenium Announces First Commercial Cellulosic Ethanol Project
10. Lafayette General Medical Center is the First Hospital in Louisiana to Use Genetic-Based Technology to Test for Respiratory Disease
11. First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Today, at the Canadian,Diabetes Association Congress, physicians ... from a phase 3b clinical study (LEAD(TM) 6) ... study showed,that liraglutide, a human GLP-1 analog administered ... glucose control (as,measured by HbA1c) than exenatide, a ...
... researchers from Penn State and the University of Texas Southwestern ... control certain proteins that catalyze biochemical reactions. "This is ... activity of a protein using light," said Stephen Benkovic, Penn ... Family Chair in Chemistry, and one of the team,s leaders. ...
... 16 The Department of Biomedical,Engineering at ... Dr.,Michael Merzenich, one of the world,s premier ... speaker at the semi-annual Allen and,Constance Ford ... in,Cleveland. The program "A revolution in neuro-therapeutics: ...
Cached Biology Technology:New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 3New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 4Scientists use light to control proteins 2Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University 2Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University 3
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... Most venomous snakes are legendary for their lethal bites, ... University of Massachusetts Lowell, explains that some cobras defend themselves ... Getting the chance to work with spitting cobras in South ... tracks aimed at his eyes. Protected by a sheet of ...
... Texas May 14, 2010 Scientists studying the ... of Louisiana and the city of New Orleans have ... exposure to chemical contaminants. The findings, published in a ... demonstrate how Hurricane Katrina caused significant ecological damage by ...
... 2010) Novel vaccines for diseases ranging from the ... research at the American Association of Pharmaceutical Scientists, (AAPS) ... government will gather at the Hilton San Francisco Union ... research and advances in biotherapeutics. Researchers from ...
Cached Biology News:Spitting cobras track first, predict later 2New research reveals Hurricane Katrina's impact on ecological and human health 2New research reveals Hurricane Katrina's impact on ecological and human health 3Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference 2
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... important role in the regulation of signaling ... Splice variants have been reported that affect ... apoptotic pathways. With Apoptosis and Cell Death ... expression profiling and at the same time ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Kit is manufactured for DNA purification from ... to UV light. The Purification of DNA ... for DNA-cloning work. The conventional method of ... of UV light damages DNA and significantly ...
Biology Products: